Previous Close | 21.63 |
Open | 21.79 |
Bid | 19.20 x 1200 |
Ask | 21.69 x 900 |
Day's Range | 21.53 - 21.79 |
52 Week Range | 17.13 - 21.90 |
Volume | |
Avg. Volume | 8,804 |
Market Cap | N/A |
Beta (5Y Monthly) | 2.05 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.58 |
Earnings Date | Nov 04, 2024 |
Forward Dividend & Yield | 1.47 (6.80%) |
Ex-Dividend Date | Aug 16, 2024 |
1y Target Est | N/A |
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce promising results from a multi-year compassionate therapy using repeated liposomal-CBD (LPT-CBD) injections for pain relief in dogs with naturally-occurring osteoarthritis. The therapy consistently demonstrated pain reduction and improved mobility, with effects lasting for several weeks after each injection as expected
Summit Hotel Properties (INN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that Dr. Joseph V. Pergolizzi, Jr., M.D., a member of Innocan's Scientific Advisory Board, has been recognized among the top 2% most-cited scientists in the world in a new list published by Stanford University. This achievement underscores Dr. Pergolizzi's long-term contribution to medical science and his influential r